Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based …

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality
among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized …

Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract
disease in older adults, but no licensed RSV vaccine currently exists. An adenovirus …

Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019,
there has been an explosion of vaccine development. By 24 September 2020, a staggering …

Background Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
elicited an equally rapid response aiming to develop a COVID-19 vaccine. These efforts are …